Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: Failure at the effector phase?

Melanoma Research

Volumn 25, Issue 4, 2015, Pages 357-361

  Chevolet, Ines ^a   Schreuer, Max ^a,b   Speeckaert, Reinhart ^a   Neyns, Bart ^b   Hoorens, Isabelle ^a   Van Geel, Nanja ^a   Krüse, Vibeke ^a   Hennart, Benjamin ^c   Allorge, Delphine ^c   Van Gele, Mireille ^a   Brochez, Lieve ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

adjuvant interferon ; indoleamine 2,3 dioxygenase; melanoma; negative feedback mechanism; programmed death ligand 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; PROGRAMMED DEATH 1 LIGAND 1; RECOMBINANT ALPHA2B INTERFERON; TRYPTOPHAN; ALPHA INTERFERON; CD274 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MALE; MELANOMA; MYELOID DENDRITIC CELL; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TREATMENT DURATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADULT; AGED; BIOSYNTHESIS; BLOOD; BONE MARROW CELL; DENDRITIC CELL; EUROPE; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; SKIN NEOPLASMS;

ADULT; AGED; ANTIGENS, CD274; CTLA-4 ANTIGEN; DENDRITIC CELLS; EUROPE; FEMALE; FLOW CYTOMETRY; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MIDDLE AGED; MYELOID CELLS; NEOPLASM STAGING; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 84936942791     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000171     Document Type: Article

References (24)

1. Ascierto PA, Gogas HJ, Grob JJ, Algarra SM, Mohr P, Hansson J, Hauschild A. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit Rev Oncol Hematol 2013; 85:149-161.
2. Eggermont AMM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383:816-827.
3. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Downregulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007; 4:e176.
4. Eggermont AM, Spatz A, Lazar V, Robert C. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol 2012; 24:137-140.
5. Ascierto PA, Chiarion-Sileni V, Muggiano A, Mandala M, Pimpinelli N, del Vecchio M, et al. Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. J Chemother 2014; 26:193-201.
6. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354:709-718.
7. Chevolet I, Speeckaert R, Haspeslagh M, Neyns B, Kruse V, Schreuer M, et al. Peritumoral indoleamine 2, 3-dioxygenase expression in melanoma: an early marker of resistance to immune control? Br J Dermatol 2014; 171:987-995.
8. Speeckaert R, Vermaelen K, van Geel N, Autier P, Lambert J, Haspeslagh M, et al. Indoleamine 2, 3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer 2012; 48:2004-2011.
9. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+ ) T cells. Sci Transl Med 2013; 5:200ra116.
10. Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, et al. Increased indoleamine 2, 3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 2009; 24:1901-1908.
11. Yamada K, Miyazaki T, Shibata T, Hara N, Tsuchiya M. Simultaneous measurement of tryptophan and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867:57-61.
12. Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, et al. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology 2015; 4:e982382.
13. Mohty AM, Grob JJ, Mohty M, Richard MA, Olive D, Gaugler B. Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. Immunobiology 2010; 215:113-123.
14. Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, et al. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 2010; 8:76.
15. Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, et al. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Translat Med 2015; 13:9.
16. Charles J, di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muhammad R, et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol 2010; 130:1646-1656.
17. Maneglier B, Rogez-Kreuz C, Spreux-Varoquaux O, Malleret B, Therond P, Samah B, et al. Comparative effects of two type I interferons, human IFNalpha and ovine IFN-tau on indoleamine-2, 3-dioxygenase in primary cultures of human macrophages. Fundam Clin Pharmacol 2007; 21:29-34.
18. Hoyo-Becerra C, Schlaak JF, Hermann DM. Insights from interferon-alpharelated depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun 2014; 42C:222-231.
19. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7:468-473.
20. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164:3596-3599.
21. Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, et al. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2, 3-dioxygenase expression. Cancer Immunol Immunother 2007; 56:1017-1024.
22. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013; 190:3783-3797.
23. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014; 63:247-257.
24. Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, et al. Longterm protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res 2007; 13:3825-3830.